Index RUT P/E - EPS (ttm) -2.71 Insider Own 33.51% Shs Outstand 26.65M Perf Week 11.48%
Market Cap 356.39M Forward P/E - EPS next Y -2.93 Insider Trans -0.67% Shs Float 21.98M Perf Month -15.05%
Income -77.22M PEG - EPS next Q -0.69 Inst Own 66.03% Short Float 5.66% Perf Quarter -33.46%
Sales 0.00M P/S - EPS this Y 77.51% Inst Trans - Short Ratio 4.03 Perf Half Y -28.23%
Book/sh 4.99 P/B 2.16 EPS next Y -4.96% ROA -60.10% Short Interest 1.24M Perf Year -
Cash/sh 5.29 P/C 2.04 EPS next 5Y - ROE -74.84% 52W Range 9.00 - 22.33 Perf YTD -19.67%
Dividend Est. - P/FCF - EPS past 5Y - ROI -44.60% 52W High -51.72% Beta -
Dividend TTM - Quick Ratio 9.38 Sales past 5Y 19.69% Gross Margin - 52W Low 19.78% ATR (14) 0.74
Dividend Ex-Date - Current Ratio 9.38 EPS Y/Y TTM - Oper. Margin 0.00% RSI (14) 47.79 Volatility 7.35% 6.54%
Employees 58 Debt/Eq 0.07 Sales Y/Y TTM - Profit Margin - Recom 1.17 Target Price 22.83
Option/Short No / Yes LT Debt/Eq 0.05 EPS Q/Q -27.58% Payout - Rel Volume 7.99 Prev Close 10.42
Sales Surprise - EPS Surprise 7.43% Sales Q/Q - Earnings Aug 12 BMO Avg Volume 308.42K Price 10.78
SMA20 -0.25% SMA50 -8.43% SMA200 -23.71% Trades
Volume 2,465,641 Change 3.45%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-13-24 Initiated Robert W. Baird
Outperform
$28
Jun-06-24 Initiated H.C. Wainwright
Buy
$22
Nov-28-23 Initiated Stifel
Buy
$20
Nov-28-23 Initiated RBC Capital Mkts
Outperform
$22
Nov-28-23 Initiated Leerink Partners
Outperform
$19
Nov-28-23 Initiated JP Morgan
Overweight
$20
Nov-28-23 Initiated Chardan Capital Markets
Buy
$23
Sep-05-24 07:30AM
Aug-12-24 07:00AM
Jul-16-24 11:03AM
Jul-15-24 04:17PM
(Investor's Business Daily) -26.08%
10:11AM
(Investor's Business Daily)
06:36AM
Loading…
06:36AM
06:00AM
Jul-11-24 08:00AM
Jul-08-24 07:00AM
May-14-24 12:00PM
09:55AM
May-09-24 07:00AM
May-07-24 07:30AM
Apr-22-24 07:30AM
Apr-16-24 07:30AM
04:22PM
Loading…
Mar-13-24 04:22PM
(GlobeNewswire) +5.67%
-5.43%
Mar-11-24 07:42AM
07:30AM
Feb-05-24 07:00AM
Jan-03-24 07:00AM
Dec-18-23 07:00AM
Dec-13-23 04:59AM
Dec-11-23 12:05PM
07:00AM
Nov-30-23 08:42AM
Nov-02-23 09:51PM
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer's disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Townsend Richard Nolan Chief Executive Officer Sep 10 '24 Option Exercise 2.33 5,000 11,650 125,695 Sep 11 05:17 PM Townsend Richard Nolan Chief Executive Officer Sep 10 '24 Sale 10.65 5,000 53,274 120,695 Sep 11 05:17 PM Richard Nolan Townsend Director Sep 10 '24 Proposed Sale 10.79 12,500 134,875 Sep 10 04:39 PM Townsend Richard Nolan Chief Executive Officer Aug 12 '24 Option Exercise 2.33 5,000 11,650 125,695 Aug 13 06:34 PM Townsend Richard Nolan Chief Executive Officer Aug 12 '24 Sale 11.53 5,000 57,634 120,695 Aug 13 06:34 PM Townsend Richard Nolan Chief Executive Officer Jul 10 '24 Option Exercise 2.33 5,000 11,650 175,695 Jul 12 04:55 PM Townsend Richard Nolan Chief Executive Officer Jul 11 '24 Sale 17.07 28,031 478,409 120,695 Jul 12 04:55 PM Townsend Richard Nolan Chief Executive Officer Jul 10 '24 Sale 16.50 26,969 444,979 148,726 Jul 12 04:55 PM Townsend Richard Nolan Chief Executive Officer Jun 10 '24 Option Exercise 2.33 5,000 11,650 175,695 Jun 12 05:00 PM Townsend Richard Nolan Chief Executive Officer Jun 10 '24 Sale 17.65 5,000 88,264 170,695 Jun 12 05:00 PM Townsend Richard Nolan Chief Executive Officer May 13 '24 Option Exercise 2.33 5,000 11,650 175,695 May 14 04:04 PM Townsend Richard Nolan Chief Executive Officer May 13 '24 Sale 13.22 5,000 66,093 170,695 May 14 04:04 PM Omega Fund VI, L.P. 10% Owner Nov 07 '23 Buy 11.00 454,545 4,999,995 2,157,623 Nov 09 08:36 PM Lundbeckfond Invest A/S 10% Owner Nov 07 '23 Buy 11.00 227,272 2,499,992 1,835,959 Nov 09 08:33 PM Longitude Capital Partners IV, 10% Owner Nov 07 '23 Buy 11.00 454,545 4,999,995 2,567,100 Nov 09 08:32 PM
Index RUT P/E - EPS (ttm) -2.20 Insider Own 24.24% Shs Outstand 44.45M Perf Week 14.05%
Market Cap 2.35B Forward P/E - EPS next Y -2.79 Insider Trans -7.53% Shs Float 41.54M Perf Month 7.11%
Income -107.85M PEG - EPS next Q -0.66 Inst Own 90.09% Short Float 14.56% Perf Quarter 19.20%
Sales 0.00M P/S - EPS this Y -13.08% Inst Trans 1.75% Short Ratio 11.11 Perf Half Y -0.21%
Book/sh 5.98 P/B 7.15 EPS next Y -9.68% ROA -36.41% Short Interest 6.05M Perf Year 161.01%
Cash/sh 7.01 P/C 6.10 EPS next 5Y - ROE -46.05% 52W Range 9.24 - 50.78 Perf YTD 178.15%
Dividend Est. - P/FCF - EPS past 5Y 10.22% ROI -28.49% 52W High -15.75% Beta 0.99
Dividend TTM - Quick Ratio 21.15 Sales past 5Y 0.00% Gross Margin - 52W Low 362.99% ATR (14) 2.17
Dividend Ex-Date - Current Ratio 21.15 EPS Y/Y TTM 33.79% Oper. Margin 0.00% RSI (14) 67.58 Volatility 6.66% 5.34%
Employees 51 Debt/Eq 0.16 Sales Y/Y TTM - Profit Margin - Recom 1.22 Target Price 61.33
Option/Short Yes / Yes LT Debt/Eq 0.15 EPS Q/Q -35.24% Payout - Rel Volume 2.42 Prev Close 41.99
Sales Surprise - EPS Surprise -10.71% Sales Q/Q - Earnings Aug 08 BMO Avg Volume 544.09K Price 42.78
SMA20 11.52% SMA50 14.56% SMA200 20.99% Trades
Volume 1,316,398 Change 1.88%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-25-24 Initiated Oppenheimer
Outperform
$26
Jan-08-24 Initiated Cantor Fitzgerald
Overweight
Dec-18-23 Initiated Raymond James
Outperform
$29
Nov-10-23 Upgrade Jefferies
Hold → Buy
$18 → $26
Aug-16-23 Initiated Guggenheim
Buy
$27
Jan-04-23 Downgrade Wedbush
Outperform → Neutral
$33 → $8
Jan-04-23 Downgrade Jefferies
Buy → Hold
$32 → $6
Jul-12-22 Initiated JP Morgan
Overweight
$35
May-02-22 Initiated H.C. Wainwright
Buy
$35
Apr-19-22 Initiated Wedbush
Outperform
$32
Sep-16-24 08:00AM
Sep-12-24 08:00AM
Sep-10-24 04:05PM
Sep-05-24 01:07AM
Sep-03-24 08:27AM
08:27AM
Loading…
08:27AM
07:49AM
Sep-02-24 06:05PM
Aug-29-24 08:00AM
Aug-09-24 04:05PM
Aug-08-24 08:00AM
Jul-05-24 04:30PM
Jul-01-24 08:00AM
Jun-11-24 04:01PM
Jun-07-24 04:05PM
04:05PM
Loading…
04:05PM
May-28-24 08:00AM
May-25-24 09:40AM
May-17-24 04:27PM
May-10-24 05:38AM
May-09-24 01:53PM
08:00AM
May-07-24 04:38PM
Apr-23-24 05:09PM
(The Wall Street Journal)
Apr-13-24 05:29AM
Apr-12-24 07:01PM
Apr-11-24 04:29PM
(Yahoo Finance Video) +17.30%
Apr-05-24 06:30PM
Apr-02-24 08:00AM
Mar-20-24 12:52PM
07:30AM
Loading…
07:30AM
Feb-28-24 04:20PM
Feb-02-24 12:40PM
08:00AM
Feb-01-24 04:05PM
Jan-29-24 11:50PM
06:15AM
Jan-25-24 06:30AM
Jan-12-24 06:44PM
Jan-08-24 08:01AM
08:00AM
Dec-27-23 08:00AM
Dec-15-23 10:15AM
Nov-14-23 05:05PM
09:55AM
Nov-09-23 09:29AM
08:00AM
Nov-04-23 10:00AM
Oct-30-23 08:00AM
Oct-18-23 09:35AM
Oct-17-23 09:35AM
Oct-16-23 09:35AM
Oct-13-23 10:22AM
Sep-26-23 04:02PM
Aug-31-23 08:00AM
Aug-16-23 10:00AM
Aug-15-23 04:03PM
Aug-10-23 08:00AM
Aug-04-23 06:30PM
Jul-24-23 09:01AM
Jul-07-23 06:35PM
Jun-27-23 08:05AM
Jun-20-23 07:04PM
09:33AM
Jun-17-23 10:10AM
Jun-15-23 04:44PM
Jun-12-23 12:05PM
Jun-11-23 01:08PM
Jun-08-23 08:00AM
Jun-07-23 08:00AM
May-11-23 08:36AM
07:30AM
May-04-23 08:00AM
Mar-28-23 07:30AM
Feb-27-23 04:05PM
Feb-14-23 07:48AM
Feb-09-23 06:51AM
05:54AM
Feb-06-23 04:05PM
Feb-01-23 09:52PM
04:01PM
Jan-30-23 07:35AM
06:00AM
Jan-25-23 08:00AM
Jan-22-23 07:39AM
Jan-06-23 05:02AM
Jan-04-23 04:07PM
(Investor's Business Daily) -64.70%
-13.31%
12:20PM
10:22AM
06:52AM
Jan-03-23 04:01PM
Dec-20-22 04:05PM
Nov-25-22 07:38AM
Nov-22-22 07:30AM
Nov-17-22 07:30AM
Nov-09-22 07:30AM
Nov-05-22 04:50PM
Oct-17-22 07:30AM
Sep-15-22 09:55AM
Sep-07-22 07:30AM
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
SEIDENBERG BETH C Director Sep 19 '24 Sale 42.31 13,823 584,793 146,553 Sep 20 04:45 PM SEIDENBERG BETH C Director Sep 18 '24 Sale 42.00 1,476 61,992 4,012 Sep 20 04:45 PM SEIDENBERG BETH C Director Sep 18 '24 Sale 42.01 1,177 49,448 160,376 Sep 20 04:45 PM BETH C SEIDENBERG Director Sep 18 '24 Proposed Sale 40.02 15,000 600,300 Sep 18 04:38 PM SAMUEL B SEIDENBERG IRREV TRUS Director Sep 18 '24 Proposed Sale 40.02 1,476 59,070 Sep 18 04:38 PM Fordyce Marshall PRESIDENT AND CEO Sep 11 '24 Option Exercise 2.90 15,625 45,262 317,246 Sep 13 04:36 PM Fordyce Marshall PRESIDENT AND CEO Sep 11 '24 Sale 37.50 15,625 585,934 307,972 Sep 13 04:36 PM MARSHALL FORDYCE Director Sep 11 '24 Proposed Sale 37.55 31,250 1,173,438 Sep 11 04:19 PM Fordyce Marshall PRESIDENT AND CEO Aug 28 '24 Option Exercise 2.90 15,625 45,262 337,592 Aug 30 04:04 PM Fordyce Marshall PRESIDENT AND CEO Aug 28 '24 Sale 36.84 30,320 1,117,140 307,972 Aug 30 04:04 PM MARSHALL FORDYCE Director Aug 28 '24 Proposed Sale 37.65 30,320 1,141,548 Aug 28 04:15 PM Fordyce Marshall PRESIDENT AND CEO Aug 21 '24 Sale 39.76 14,471 575,425 322,667 Aug 23 05:40 PM Fordyce Marshall PRESIDENT AND CEO Aug 14 '24 Option Exercise 2.90 15,625 45,262 352,763 Aug 16 04:31 PM Fordyce Marshall PRESIDENT AND CEO Aug 14 '24 Sale 37.56 15,625 586,927 337,138 Aug 16 04:31 PM MARSHALL FORDYCE Director Aug 14 '24 Proposed Sale 37.95 15,625 592,969 Aug 14 04:24 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR May 16 '24 Option Exercise 7.87 20,651 162,523 69,357 May 17 04:21 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR May 15 '24 Option Exercise 3.94 8,221 32,387 61,392 May 17 04:21 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR May 16 '24 Sale 42.32 20,651 873,890 51,206 May 17 04:21 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR May 15 '24 Sale 42.27 10,186 430,546 51,206 May 17 04:21 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR Apr 10 '24 Sale 40.00 5,714 228,560 53,171 Apr 12 04:02 PM Grant Sean CHIEF FINANCIAL OFFICER Apr 03 '24 Option Exercise 14.87 99,828 1,484,442 166,165 Apr 05 09:32 PM Grant Sean CHIEF FINANCIAL OFFICER Apr 03 '24 Sale 39.61 99,828 3,954,516 66,337 Apr 05 09:32 PM Grant Sean CHIEF FINANCIAL OFFICER Apr 03 '24 Sale 39.42 18,649 735,205 0 Apr 05 09:32 PM Katabi Maha Director Mar 22 '24 Sale 40.51 413,450 16,748,860 3,133,987 Mar 25 09:46 PM Katabi Maha Director Mar 25 '24 Sale 40.50 340,000 13,770,000 2,793,987 Mar 25 09:46 PM Katabi Maha Director Mar 21 '24 Sale 44.20 81,009 3,580,723 3,547,437 Mar 25 09:46 PM Katabi Maha Director Jan 30 '24 Buy 31.00 161,290 4,999,990 3,628,446 Feb 01 05:58 PM COMMODORE CAPITAL LP 10% Owner Jan 10 '24 Sale 18.00 1,050,000 18,900,000 4,400,000 Jan 12 09:55 PM Fordyce Marshall President and CEO Dec 29 '23 Option Exercise 2.87 13,516 38,854 256,877 Jan 03 04:15 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
